30461214|t|The PPARalpha agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia.
30461214|a|AIMS: Prenatal maternal immune activation (MIA) is associated with a risk to develop schizophrenia and affects dopamine systems in the ventral tegmental area (VTA), key region in the neurobiology of psychoses. Considering the well-described sex differences in schizophrenia, we investigated whether sex affects MIA impact on dopamine system and on schizophrenia-related behavioral phenotype. Furthermore, considering peroxisome proliferator-activated receptor-alpha (PPARalpha) expression in the CNS as well as its anti-inflammatory and neuroprotective properties, we tested if PPARalpha activation by prenatal treatment with a clinically available fibrate (fenofibrate) may mitigate MIA-related effects. METHODS: We induced MIA in rat dams with polyriboinosinic-polyribocytidylic acid (Poly I:C) and assessed prepulse inhibition and dopamine neuron activity in the VTA by means of electrophysiological recordings in male and female preweaned and adult offspring. RESULTS: Poly I:C-treated males displayed prepulse inhibition deficits, reduced number and firing rate of VTA dopamine neurons, and paired-pulse facilitation of inhibitory and excitatory synapses. Prenatal fenofibrate administration attenuated detrimental effects induced by MIA on both the schizophrenia-like behavioral phenotype and dopamine transmission in male offspring. CONCLUSION: Our study confirms previous evidence that females are less susceptible to MIA and highlights PPARalpha as a potential target for treatments in schizophrenia.
30461214	4	13	PPARalpha	Gene	25747
30461214	22	33	fenofibrate	Chemical	MESH:D011345
30461214	59	67	dopamine	Chemical	MESH:D004298
30461214	109	112	rat	Species	10116
30461214	122	135	schizophrenia	Disease	MESH:D012559
30461214	222	235	schizophrenia	Disease	MESH:D012559
30461214	248	256	dopamine	Chemical	MESH:D004298
30461214	336	345	psychoses	Disease	MESH:D011618
30461214	397	410	schizophrenia	Disease	MESH:D012559
30461214	462	470	dopamine	Chemical	MESH:D004298
30461214	485	498	schizophrenia	Disease	MESH:D012559
30461214	554	602	peroxisome proliferator-activated receptor-alpha	Gene	25747
30461214	604	613	PPARalpha	Gene	25747
30461214	657	669	inflammatory	Disease	MESH:D007249
30461214	715	724	PPARalpha	Gene	25747
30461214	786	793	fibrate	Chemical	MESH:D058607
30461214	795	806	fenofibrate	Chemical	MESH:D011345
30461214	869	872	rat	Species	10116
30461214	883	922	polyriboinosinic-polyribocytidylic acid	Chemical	MESH:D011070
30461214	924	932	Poly I:C	Chemical	MESH:D011070
30461214	971	979	dopamine	Chemical	MESH:D004298
30461214	1110	1118	Poly I:C	Chemical	MESH:D011070
30461214	1211	1219	dopamine	Chemical	MESH:D004298
30461214	1307	1318	fenofibrate	Chemical	MESH:D011345
30461214	1392	1405	schizophrenia	Disease	MESH:D012559
30461214	1436	1444	dopamine	Chemical	MESH:D004298
30461214	1582	1591	PPARalpha	Gene	25747
30461214	1632	1645	schizophrenia	Disease	MESH:D012559
30461214	Association	MESH:D004298	MESH:D012559
30461214	Negative_Correlation	MESH:D004298	MESH:D011345
30461214	Association	MESH:D012559	25747
30461214	Negative_Correlation	MESH:D011345	MESH:D012559
30461214	Positive_Correlation	MESH:D011345	25747
30461214	Association	MESH:D004298	MESH:D011618
30461214	Association	MESH:D004298	25747
30461214	Negative_Correlation	MESH:D007249	25747
30461214	Negative_Correlation	MESH:D004298	MESH:D011070

